Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care?

David J. Restrepo, Maria T. Huayllani, Daniel Boczar, Andrea Sisti, Emmanuel Gabriel, Riccardo Lemini, Aaron C. Spaulding, Sanjay Bagaria, Oscar J. Manrique, Antonio J. Forte

Research output: Contribution to journalArticle

Abstract

BACKGROUND/AIM: To analyze whether demographic and facility type characteristics cause inequality in the type of biopsy performed in patients with cutaneous melanoma. PATIENTS AND METHODS: The skin cancer National Cancer Database was assessed. Men and women of all ages with cutaneous melanoma in situ and malignant melanoma at any stage of the disease were included. Patients were selected who underwent one of the following biopsy types: excisional, punch, shave, or incisional. Bivariate and multivariate analyses were performed. RESULTS: We found that the likelihood of undergoing an excisional biopsy decreased in patients who were: Hispanic [odds ratio (OR)=0.63, confidence interval (CI)=0.55-0.71], non-White (OR=0.66, CI=0.58-0.76), older than 80 years (OR=0.77, CI=0.72-0.87), or in Comprehensive Community Cancer Programs (OR=0.33, CI=0.31-0.36), Community Cancer Programs (OR=0.52, CI=0.50-0.54) and Integrated Network Cancer Programs (OR=0.58, CI=0.55-0.61). CONCLUSION: Our study results demonstrate disparities in biopsy type in the treatment of melanoma.

Original languageEnglish (US)
Pages (from-to)6359-6363
Number of pages5
JournalAnticancer research
Volume39
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Standard of Care
Melanoma
Odds Ratio
Confidence Intervals
Biopsy
Neoplasms
Skin
Skin Neoplasms
Hispanic Americans
Multivariate Analysis
Demography
Databases

Keywords

  • biopsy
  • disparities
  • Melanoma
  • socioeconomic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Restrepo, D. J., Huayllani, M. T., Boczar, D., Sisti, A., Gabriel, E., Lemini, R., ... Forte, A. J. (2019). Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care? Anticancer research, 39(11), 6359-6363. https://doi.org/10.21873/anticanres.13848

Biopsy Type Disparities in Patients With Melanoma : Who Receives the Standard of Care? / Restrepo, David J.; Huayllani, Maria T.; Boczar, Daniel; Sisti, Andrea; Gabriel, Emmanuel; Lemini, Riccardo; Spaulding, Aaron C.; Bagaria, Sanjay; Manrique, Oscar J.; Forte, Antonio J.

In: Anticancer research, Vol. 39, No. 11, 01.11.2019, p. 6359-6363.

Research output: Contribution to journalArticle

Restrepo, DJ, Huayllani, MT, Boczar, D, Sisti, A, Gabriel, E, Lemini, R, Spaulding, AC, Bagaria, S, Manrique, OJ & Forte, AJ 2019, 'Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care?', Anticancer research, vol. 39, no. 11, pp. 6359-6363. https://doi.org/10.21873/anticanres.13848
Restrepo DJ, Huayllani MT, Boczar D, Sisti A, Gabriel E, Lemini R et al. Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care? Anticancer research. 2019 Nov 1;39(11):6359-6363. https://doi.org/10.21873/anticanres.13848
Restrepo, David J. ; Huayllani, Maria T. ; Boczar, Daniel ; Sisti, Andrea ; Gabriel, Emmanuel ; Lemini, Riccardo ; Spaulding, Aaron C. ; Bagaria, Sanjay ; Manrique, Oscar J. ; Forte, Antonio J. / Biopsy Type Disparities in Patients With Melanoma : Who Receives the Standard of Care?. In: Anticancer research. 2019 ; Vol. 39, No. 11. pp. 6359-6363.
@article{cc49c61a56e848648ca89d34d66a507c,
title = "Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care?",
abstract = "BACKGROUND/AIM: To analyze whether demographic and facility type characteristics cause inequality in the type of biopsy performed in patients with cutaneous melanoma. PATIENTS AND METHODS: The skin cancer National Cancer Database was assessed. Men and women of all ages with cutaneous melanoma in situ and malignant melanoma at any stage of the disease were included. Patients were selected who underwent one of the following biopsy types: excisional, punch, shave, or incisional. Bivariate and multivariate analyses were performed. RESULTS: We found that the likelihood of undergoing an excisional biopsy decreased in patients who were: Hispanic [odds ratio (OR)=0.63, confidence interval (CI)=0.55-0.71], non-White (OR=0.66, CI=0.58-0.76), older than 80 years (OR=0.77, CI=0.72-0.87), or in Comprehensive Community Cancer Programs (OR=0.33, CI=0.31-0.36), Community Cancer Programs (OR=0.52, CI=0.50-0.54) and Integrated Network Cancer Programs (OR=0.58, CI=0.55-0.61). CONCLUSION: Our study results demonstrate disparities in biopsy type in the treatment of melanoma.",
keywords = "biopsy, disparities, Melanoma, socioeconomic factors",
author = "Restrepo, {David J.} and Huayllani, {Maria T.} and Daniel Boczar and Andrea Sisti and Emmanuel Gabriel and Riccardo Lemini and Spaulding, {Aaron C.} and Sanjay Bagaria and Manrique, {Oscar J.} and Forte, {Antonio J.}",
year = "2019",
month = "11",
day = "1",
doi = "10.21873/anticanres.13848",
language = "English (US)",
volume = "39",
pages = "6359--6363",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Biopsy Type Disparities in Patients With Melanoma

T2 - Who Receives the Standard of Care?

AU - Restrepo, David J.

AU - Huayllani, Maria T.

AU - Boczar, Daniel

AU - Sisti, Andrea

AU - Gabriel, Emmanuel

AU - Lemini, Riccardo

AU - Spaulding, Aaron C.

AU - Bagaria, Sanjay

AU - Manrique, Oscar J.

AU - Forte, Antonio J.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND/AIM: To analyze whether demographic and facility type characteristics cause inequality in the type of biopsy performed in patients with cutaneous melanoma. PATIENTS AND METHODS: The skin cancer National Cancer Database was assessed. Men and women of all ages with cutaneous melanoma in situ and malignant melanoma at any stage of the disease were included. Patients were selected who underwent one of the following biopsy types: excisional, punch, shave, or incisional. Bivariate and multivariate analyses were performed. RESULTS: We found that the likelihood of undergoing an excisional biopsy decreased in patients who were: Hispanic [odds ratio (OR)=0.63, confidence interval (CI)=0.55-0.71], non-White (OR=0.66, CI=0.58-0.76), older than 80 years (OR=0.77, CI=0.72-0.87), or in Comprehensive Community Cancer Programs (OR=0.33, CI=0.31-0.36), Community Cancer Programs (OR=0.52, CI=0.50-0.54) and Integrated Network Cancer Programs (OR=0.58, CI=0.55-0.61). CONCLUSION: Our study results demonstrate disparities in biopsy type in the treatment of melanoma.

AB - BACKGROUND/AIM: To analyze whether demographic and facility type characteristics cause inequality in the type of biopsy performed in patients with cutaneous melanoma. PATIENTS AND METHODS: The skin cancer National Cancer Database was assessed. Men and women of all ages with cutaneous melanoma in situ and malignant melanoma at any stage of the disease were included. Patients were selected who underwent one of the following biopsy types: excisional, punch, shave, or incisional. Bivariate and multivariate analyses were performed. RESULTS: We found that the likelihood of undergoing an excisional biopsy decreased in patients who were: Hispanic [odds ratio (OR)=0.63, confidence interval (CI)=0.55-0.71], non-White (OR=0.66, CI=0.58-0.76), older than 80 years (OR=0.77, CI=0.72-0.87), or in Comprehensive Community Cancer Programs (OR=0.33, CI=0.31-0.36), Community Cancer Programs (OR=0.52, CI=0.50-0.54) and Integrated Network Cancer Programs (OR=0.58, CI=0.55-0.61). CONCLUSION: Our study results demonstrate disparities in biopsy type in the treatment of melanoma.

KW - biopsy

KW - disparities

KW - Melanoma

KW - socioeconomic factors

UR - http://www.scopus.com/inward/record.url?scp=85074714713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074714713&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13848

DO - 10.21873/anticanres.13848

M3 - Article

C2 - 31704868

AN - SCOPUS:85074714713

VL - 39

SP - 6359

EP - 6363

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -